Seeking Alpha

Biogen Idec (BIIB +2.6%) moves up after saying it and Swedish Orphan Biovitrum released data...

Biogen Idec (BIIB +2.6%) moves up after saying it and Swedish Orphan Biovitrum released data that confirms the ability of its investigational recombinant factors VIII Fc fusion protein and IX Fc fusion protein to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia. Separately, Citigroup throws in the towel and ups the shares to Buy, saying the fundamentals are just too strong to look for any pullback opportunity to pick the shares up cheaper.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs